- Home
- PHT vs DRUG Comparison
PHT vs DRUG Comparison
Compare PHT & DRUG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHT
- DRUG
- Stock Information
- Founded
- PHT 2002
- DRUG 2019
- Country
- PHT United States
- DRUG United States
- Employees
- PHT N/A
- DRUG N/A
- Industry
- PHT Investment Managers
- DRUG Pharmaceuticals and Biotechnology
- Sector
- PHT Finance
- DRUG Health Care
- Exchange
- PHT Nasdaq
- DRUG Nasdaq
- Market Cap
- PHT 232.7M
- DRUG 260.6M
- IPO Year
- PHT N/A
- DRUG N/A
- Fundamental
- Price
- PHT $7.75
- DRUG $38.77
- Analyst Decision
- PHT
- DRUG Buy
- Analyst Count
- PHT 0
- DRUG 1
- Target Price
- PHT N/A
- DRUG $75.00
- AVG Volume (30 Days)
- PHT 85.5K
- DRUG 155.7K
- Earning Date
- PHT 01-01-0001
- DRUG 02-11-2025
- Dividend Yield
- PHT 8.76%
- DRUG N/A
- EPS Growth
- PHT N/A
- DRUG N/A
- EPS
- PHT 0.98
- DRUG N/A
- Revenue
- PHT N/A
- DRUG N/A
- Revenue This Year
- PHT N/A
- DRUG N/A
- Revenue Next Year
- PHT N/A
- DRUG N/A
- P/E Ratio
- PHT $7.71
- DRUG N/A
- Revenue Growth
- PHT N/A
- DRUG N/A
- 52 Week Low
- PHT $6.41
- DRUG $0.93
- 52 Week High
- PHT $7.60
- DRUG $79.02
- Technical
- Relative Strength Index (RSI)
- PHT 29.82
- DRUG 50.21
- Support Level
- PHT $7.94
- DRUG $36.35
- Resistance Level
- PHT $7.91
- DRUG $42.85
- Average True Range (ATR)
- PHT 0.05
- DRUG 3.95
- MACD
- PHT -0.03
- DRUG -0.43
- Stochastic Oscillator
- PHT 0.00
- DRUG 22.76
About PHT Pioneer High Income Fund Inc.
Pioneer High Income Trust is a closed-end management investment company. Its investment objective is to provide a high level of current income and to seek capital appreciation by investing predominantly in below investment grade (high-yield) debt securities, loans, and preferred stocks.
About DRUG Bright Minds Biosciences Inc.
Bright Minds Biosciences Inc is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as resistant epilepsy, treatment resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.